Financials Apontis Pharma AG Deutsche Boerse AG

Equities

APPH

DE000A3CMGM5

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 08:44:00 16/07/2024 BST			5-day change	1st Jan Change
8.73 ^EUR	-0.80%		+0.94%	+84.19%

06-27	Apontis Pharma AG Appoints Thomas Zimmermann to the Management Board, Effective 1 July 2024	CI
04-05	Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	MT

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	170	69.7	39.57	72.64	-	-
Enterprise Value (EV) ¹	140.2	33.35	18.77	63.01	62.45	56.16
P/E ratio	-227 x	25.9 x	-3.57 x	58.1 x	18.6 x	10.1 x
Yield	-	-	-	-	-	-
Capitalization / Revenue	3.32 x	1.25 x	1.07 x	1.42 x	1.23 x	1.03 x
EV / Revenue	2.74 x	0.6 x	0.51 x	1.23 x	1.05 x	0.8 x
EV / EBITDA	28.8 x	5.99 x	-1.41 x	17.1 x	7.69 x	4.11 x
EV / FCF	79 x	4.31 x	-1.18 x	-5.94 x	116 x	8.93 x
FCF Yield	1.27%	23.2%	-84.5%	-16.8%	0.87%	11.2%
Price to Book	4.18 x	1.64 x	1.31 x	2.36 x	2.09 x	1.73 x
Nbr of stocks (in thousands)	8,500	8,500	8,330	8,330	-	-
Reference price ²	20.00	8.200	4.750	8.720	8.720	8.720
Announcement Date	30/03/22	30/03/23	28/03/24	-	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	39.24	51.18	55.73	36.96	51.18	59.29	70.64
EBITDA ¹	-	4.862	5.569	-13.28	3.676	8.125	13.66
EBIT ¹	-	3.116	3.876	-15.16	1.658	5.505	10.13
Operating Margin	-	6.09%	6.96%	-41.02%	3.24%	9.29%	14.34%
Earnings before Tax (EBT) ¹	-	0.2483	3.828	-14.85	1.752	5.54	10.17
Net income ¹	-1.183	-0.7452	2.689	-11.3	1.256	4.015	7.372
Net margin	-3.01%	-1.46%	4.82%	-30.58%	2.45%	6.77%	10.44%
EPS ²	-	-0.0880	0.3163	-1.330	0.1500	0.4700	0.8675
Free Cash Flow ¹	-	1.773	7.742	-15.86	-10.61	0.5405	6.288
FCF margin	-	3.46%	13.89%	-42.9%	-20.73%	0.91%	8.9%
FCF Conversion (EBITDA)	-	36.48%	139.02%	-	-	6.65%	46.05%
FCF Conversion (Net income)	-	-	287.93%	-	-	13.46%	85.3%
Dividend per Share ²	-	-	-	-	-	-	-
Announcement Date	29/04/21	30/03/22	30/03/23	28/03/24	-	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2021 S1	2021 Q3	2022 S1	2024 Q1	2024 Q2
Net sales ¹	24.01	12.69	-	10.5	9.8
EBITDA	-	1.566	-	-	0.9
EBIT	-	1.227	-	-	-
Operating Margin	-	9.67%	-	-	-
Earnings before Tax (EBT)	-	-	2.389	-	-
Net income	-2.197	-	2.351	-	-
Net margin	-9.15%	-	-	-	-
EPS	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	11/08/21	18/11/21	11/08/22	-	-

¹EUR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-
Net Cash position ¹	-	29.8	36.3	20.8	9.63	10.2	16.5
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	-	1.77	7.74	-15.9	-10.6	0.54	6.29
ROE (net income / shareholders' equity)	-	7.95%	6.54%	-31.5%	4.03%	11.7%	18.8%
ROA (Net income/ Total Assets)	-	-	4.72%	-19.3%	2.7%	6.9%	12.2%
Assets ¹	-	-	56.99	58.66	46.53	58.19	60.42
Book Value Per Share ²	-	4.790	4.990	3.630	3.700	4.170	5.050
Cash Flow per Share	-	-	-	-	-	-	-
Capex ¹	-	1.66	3.28	3.26	4.23	6.75	4.73
Capex / Sales	-	3.24%	5.88%	8.83%	8.26%	11.39%	6.69%
Announcement Date	29/04/21	30/03/22	30/03/23	28/03/24	-	-	-

¹EUR in Million²EUR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Apontis Pharma AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.72 EUR

Average target price

17.38 EUR

Spread / Average Target

+99.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.06%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.74%	244B
ROCHE HOLDING AG	+5.03%	234B
NOVARTIS AG	+16.57%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals